Here, we report the isolation of Mycobacterium orygis from dairy cattle in Chennai, India. Spoligotyping assigned the isolate to spoligotype 587 (ST587), which belongs to M. orygis. This species was confirmed as M. orygis using wholegenome sequencing.
quality of Ͼ50, a mapping quality of Ͼ30, and a depth of at least 5 with at least one read in either direction were filtered for analysis. RD-Analyzer v1.0 (default parameters) was used to detect regions of difference (RDs; regions of the MTBC genome whose presence or absence is lineage specific and that are widely used as classification markers) (15) . Filtered reads were also assembled with SPAdes v3.11.0 with autocorrection (16) .
Comparison of the spoligotype profile with those in the SpolDB4 database classified the isolate as spoligotype 587 (ST587), which belongs to M. orygis (1) . RD-Analyzer results confirmed the absence of RD7, RD8, RD9, and RD10 and the presence of RD1 and RD4 (1) . The assembled genome (size, 4,293,394 bp) consisted of 107 contigs with an N 50 value of 99,756 bp and a GϩC content of 65.59%. Analysis of identified variants revealed a previously reported T-to-G mutation in the 38th codon of Rv2042c and a C-to-T mutation at the 321st codon in the gene PPE55 (3). These genomic features, along with the spoligotyping results, confirmed the strain to be M. orygis. This genome sequence will contribute to our understanding of the genomic characteristics of this species and will facilitate further comparative genomic studies.
Data availability. This whole-genome shotgun project has been submitted to NCBI under BioProject identifier PRJNA545406. The raw reads and the assembled contigs have been submitted under accession numbers SRR9157804 and VDER00000000, respectively. The version of the assembled contigs described in this paper is the first version, VDER01000000.
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